Chitosan modified with PAP as a Promising Delivery System for Melatonin in the Treatment of Osteoporosis : Targeting the DMT1

Abstract

Abstract The demand of novel and efficient therapy gradually increased with the rising concerns of Osteoporosis (OP). The hottest topic to promote bone regeneration under osteoporotic conditions consists of loading bioactive materials with different drugs to treat osteoporotic bone by either promoting the osteogenesis process or inhibiting the activity of osteoclasts. By analyzing the single-cell sequencing results, we found that divalent metal transporter 1 (DMT1) has a function in osteoporosis. Based on our previous research foundation, Melatonin(MT) could suppress DMT1 express induced by high glucose in Osteoporosis. So, we are more determined to choose MT for the treatment of osteoporosis. However, the curative effect of MT in osteoporosis was dissatisfied in clinical. To enhance its biological performance, we combined MT with porous gelatin Chitosan (CS) and conductive material PLA-b-AP-b-PLA (PAP), we investigated how MT incorporation in CS@PAP nanoparticles impacts their ability to promote MC3T3-E1 osteogenesis and mineralization in vitro and vivo. Herein, the present study confirms the effect of MT in DMT1, prepared and explore available on composites prepared as nanofibers characteristics, the efficacy of MT combined CS-PAP modified hydrogels slow release systems in femur model of osteoporosis mice, associated properties found suitable for bone tissue engineering. May present a new strategy for OP patients management. The results indicate that MT-loaded CS@PAP nanospheres shows favorable osteogenic function in vivo and vitro.